Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 823763, 5 pages
http://dx.doi.org/10.1155/2014/823763
Clinical Study

Methotrexate-Associated Nonalcoholic Fatty Liver Disease with Transaminitis in Rheumatoid Arthritis

1Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore 308433
2Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia

Received 26 January 2014; Revised 3 May 2014; Accepted 17 May 2014; Published 28 May 2014

Academic Editor: Raimon Sanmartí

Copyright © 2014 Rajalingham Sakthiswary et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Combe, R. Landewe, C. Lukas et al., “EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT),” Annals of the Rheumatic Diseases, vol. 66, no. 1, pp. 34–45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. K. G. Saag, G. T. Gim, N. M. Patkar et al., “American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis,” Arthritis Care and Research, vol. 59, no. 6, pp. 762–784, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Salliot and D. van der Heijde, “Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1100–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. E. van Ede, R. F. Laan, H. J. Blom et al., “The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients,” Arthritis and Rheumatism, vol. 44, no. 11, pp. 2525–2530, 2001. View at Google Scholar
  5. E. Quintin, J.-Y. Scoazec, H. Marotte, and P. Miossec, “Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes,” Arthritis Research and Therapy, vol. 12, no. 4, article R143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Penalva Polo, A. Gómez Andrés, P. Vela, and M. Niveiro, “Acute liver failure in a patient with methotrexate therapy,” Revista Espanola de Enfermedades Digestivas, vol. 94, no. 7, pp. 440–441, 2002. View at Google Scholar · View at Scopus
  7. N. S. Hakim, B. Kobienia, E. Benedetti, J. Bloomer, and W. D. Payne, “Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis,” International Surgery, vol. 83, no. 3, pp. 224–225, 1998. View at Google Scholar · View at Scopus
  8. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” Hepatology, vol. 55, no. 6, pp. 2005–2023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Rau, T. Karger, G. Herborn, and H. Frenzel, “Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate,” The Journal of Rheumatology, vol. 16, no. 4, pp. 489–493, 1989. View at Google Scholar · View at Scopus
  10. L. A. Adams and P. Angulo, “Treatment of non-alcoholic fatty liver disease,” Postgraduate Medical Journal, vol. 82, no. 967, pp. 315–322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. E. van Ede, R. F. J. M. Laan, H. J. Blom, R. A. de Abreu, and L. B. A. van de Putte, “Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity,” Seminars in Arthritis and Rheumatism, vol. 27, no. 5, pp. 277–292, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Kremer, J. Galivan, A. Streckfuss, and B. Kamen, “Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates,” Arthritis and Rheumatism, vol. 29, no. 7, pp. 832–835, 1986. View at Google Scholar · View at Scopus
  13. P. Ranganathan, S. Eisen, W. M. Yokoyama, and H. L. McLeod, “Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?” Annals of the Rheumatic Diseases, vol. 62, no. 1, pp. 4–9, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Urano, A. Taniguchi, H. Yamanaka et al., “Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses,” Pharmacogenetics, vol. 12, no. 3, pp. 183–190, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. S. R. Mehta, E. L. Thomas, J. D. Bell, D. G. Johnston, and S. D. Taylor-Robinson, “Non-invasive means of measuring hepatic fat content,” World Journal of Gastroenterology, vol. 14, no. 22, pp. 3476–3483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Foster, F. A. Anania, D. Li, R. Katz, and M. Budoff, “The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA),” Digestive Diseases and Sciences, vol. 58, no. 8, pp. 2392–2398, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Niaz, Z. Ali, S. Nayyar, and N. Fatima, “Prevalence of NAFLD in healthy and young male individuals,” ISRN Gastroenterology, vol. 2011, Article ID 363546, 4 pages, 2011. View at Publisher · View at Google Scholar
  18. K. Visser and D. M. F. M. van der Heijde, “Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature,” Clinical and Experimental Rheumatology, vol. 27, no. 6, pp. 1017–1025, 2009. View at Google Scholar · View at Scopus
  19. A. M. Walker, D. Funch, N. A. Dreyer et al., “Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis,” Arthritis and Rheumatism, vol. 36, no. 3, pp. 329–335, 1993. View at Google Scholar · View at Scopus
  20. R. Cáliz, J. del Amo, A. Balsa et al., “The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population,” Scandinavian Journal of Rheumatology, vol. 41, no. 1, pp. 10–14, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Malik and P. Ranganathan, “Methotrexate pharmacogenetics in rheumatoid arthritis: a status report,” Pharmacogenomics, vol. 14, no. 3, pp. 305–314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S. A. Owen, M. Lunt, J. Bowes et al., “MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms,” Pharmacogenomics Journal, vol. 13, no. 2, pp. 137–147, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Gaiani, A. Avogaro, G. C. Bombonato et al., “Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: prevalence and relationships with hemodynamic alterations detected with Doppler sonography,” Journal of Ultrasound, vol. 12, no. 1, pp. 1–5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Ortiz-Lopez, R. Lomonaco, B. Orsak et al., “Prevalence of prediabetes and diabetes and metabolic profile of patients with Nonalcoholic Fatty Liver Disease (NAFLD),” Diabetes Care, vol. 35, no. 4, pp. 873–878, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. J. R. Curtis, T. Beukelman, A. Onofrei et al., “Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 43–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Kremer, M. C. Genovese, G. W. Cannon et al., “Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial,” Annals of Internal Medicine, vol. 137, no. 9, pp. 726–733, 2002. View at Google Scholar · View at Scopus